'Rejuvenation' protects neurons in mouse models of Parkinson's disease
- PMID: 17558391
- DOI: 10.1038/nature05865
'Rejuvenation' protects neurons in mouse models of Parkinson's disease
Abstract
Why dopamine-containing neurons of the brain's substantia nigra pars compacta die in Parkinson's disease has been an enduring mystery. Our studies suggest that the unusual reliance of these neurons on L-type Ca(v)1.3 Ca2+ channels to drive their maintained, rhythmic pacemaking renders them vulnerable to stressors thought to contribute to disease progression. The reliance on these channels increases with age, as juvenile dopamine-containing neurons in the substantia nigra pars compacta use pacemaking mechanisms common to neurons not affected in Parkinson's disease. These mechanisms remain latent in adulthood, and blocking Ca(v)1.3 Ca2+ channels in adult neurons induces a reversion to the juvenile form of pacemaking. Such blocking ('rejuvenation') protects these neurons in both in vitro and in vivo models of Parkinson's disease, pointing to a new strategy that could slow or stop the progression of the disease.
Comment in
-
Neurophysiology: stressful pacemaking.Nature. 2007 Jun 28;447(7148):1059-60. doi: 10.1038/4471059a. Nature. 2007. PMID: 17597746 No abstract available.
Similar articles
-
Neurophysiology: stressful pacemaking.Nature. 2007 Jun 28;447(7148):1059-60. doi: 10.1038/4471059a. Nature. 2007. PMID: 17597746 No abstract available.
-
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.Neuroscience. 2006 Jun 19;140(1):67-76. doi: 10.1016/j.neuroscience.2006.02.007. Epub 2006 Mar 14. Neuroscience. 2006. PMID: 16533572
-
A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease.Mov Disord. 2010;25 Suppl 1:S63-70. doi: 10.1002/mds.22801. Mov Disord. 2010. PMID: 20187241
-
Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.Cell Calcium. 2010 Feb;47(2):175-82. doi: 10.1016/j.ceca.2009.12.003. Epub 2010 Jan 6. Cell Calcium. 2010. PMID: 20053445 Free PMC article. Review.
-
Calcium, ageing, and neuronal vulnerability in Parkinson's disease.Lancet Neurol. 2007 Oct;6(10):933-8. doi: 10.1016/S1474-4422(07)70246-6. Lancet Neurol. 2007. PMID: 17884683 Review.
Cited by
-
Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features.Neurol Sci. 2013 May;34(5):621-7. doi: 10.1007/s10072-012-1251-2. Epub 2012 Nov 30. Neurol Sci. 2013. PMID: 23192440 Review.
-
L-type calcium channels as drug targets in CNS disorders.Channels (Austin). 2016;10(1):7-13. doi: 10.1080/19336950.2015.1048936. Epub 2015 Jun 3. Channels (Austin). 2016. PMID: 26039257 Free PMC article. Review.
-
AMP kinase regulates ligand-gated K-ATP channels in substantia nigra dopamine neurons.Neuroscience. 2016 Aug 25;330:219-28. doi: 10.1016/j.neuroscience.2016.06.001. Epub 2016 Jun 5. Neuroscience. 2016. PMID: 27267246 Free PMC article.
-
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.J Med Chem. 2013 Apr 25;56(8):3121-47. doi: 10.1021/jm3015926. Epub 2013 Mar 27. J Med Chem. 2013. PMID: 23458846 Free PMC article. Review.
-
Harpagide, a natural product, promotes synaptic vesicle release as measured by nanoelectrode amperometry.Chem Sci. 2019 Nov 28;11(3):778-785. doi: 10.1039/c9sc05538j. Chem Sci. 2019. PMID: 34123052 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous